Effects of pimobendan on systolic function and inflammatory biomarkers in dogs with chronic degenerative mitral valve disease (endocardiosios, myxomatous mitral valve disease)
We are seeking patients for inclusion in a new clinical trial on the acute effects of pimobendan in dogs. Chronic treatment with Pimobendan has been shown to have positive effects on both quality of life and survival in dogs with chronic degenerative mitral valve disease. However, there is some evidence that short-term administration of the drug can be efficacious.
The aim of this study is to clarify the short-term benefits of pimobendan administration in dogs.
For this study, we are searching for patients with a previous diagnosis of chronic degenerative mitral valve disease treated for at least one month with furosemide (a diuretic) and an ACE-inhibitor (enalapril, benazepril or ramipril). This study has been approved by the Kansas State University Institutional Animal Care and Use Committee (IACUC).
Each participant receives two complete cardiac evaluations including echocardiogram and thoracic radiographs and a three month supply of pimobendan. If you are interested in enrolling your pet in this study please contact our service. We strongly recommend you discuss this with your veterinarian first.
Your pet’s participationwill be of great value in helping veterinary cardiologists better understand this important cardiac disease in dogs.